Related references
Note: Only part of the references are listed.Association of Structural Entheseal Lesions With an Increased Risk of Progression From Psoriasis to Psoriatic Arthritis
David Simon et al.
ARTHRITIS & RHEUMATOLOGY (2022)
JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function
Susanne Adam et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis
Daniel Regan-Komito et al.
NATURE COMMUNICATIONS (2020)
Normal human enthesis harbours conventional CD4+and CD8+T cells with regulatory features and inducible IL-17A and TNF expression
Abdulla Watad et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis
Stefano Alivernini et al.
NATURE MEDICINE (2020)
Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II)
Silvio Danese et al.
GUT (2019)
Expansion of IL-23 receptor bearing TNFR2+T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease
Heike Schmitt et al.
GUT (2019)
Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Elizabeth G. Araujo et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
Frances Humby et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Jose U. Scher et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Distinct fibroblast subsets drive inflammation and damage in arthritis
Adam P. Croft et al.
NATURE (2019)
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Markus F. Neurath
NATURE IMMUNOLOGY (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Locally renewing resident synovial macrophages provide a protective barrier for the joint
Stephan Culemann et al.
NATURE (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study
Laura Savage et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators
Charles N. Serhan et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study
Sudha Visvanathan et al.
JOURNAL OF CROHNS & COLITIS (2018)
Association of Inflammatory Bowel Disease and Acute Anterior Uveitis, but Not Psoriasis, With Disease Duration in Patients With Axial Spondyloarthritis Results From Two Belgian Nationwide Axial Spondyloarthritis Cohorts
Gaelle Varkas et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
Philip J. Mease et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis
Isabelle Cambre et al.
NATURE COMMUNICATIONS (2018)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
Brian G. Feagan et al.
LANCET (2017)
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Daniella M. Schwartz et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Psoriatic Arthritis
Christopher T. Ritchlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of DMARDs on citrullinated peptide autoantibody levels in RA patients-A longitudinal analysis
Carolin Wunderlich et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies
Roy Fleischmann et al.
RMD OPEN (2017)
A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis
Eric Gracey et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
Johannes W. J. Bijlsma et al.
LANCET (2016)
Ankylosing Spondylitis and Axial Spondyloarthritis
Joel D. Taurog et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy
Neal L. Millar et al.
SCIENTIFIC REPORTS (2016)
Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials
Xavier M. Teitsma et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Functional Brain Imaging Reveals Rapid Blockade of Abdominal Pain Response Upon Anti-TNF Therapy in Crohn's Disease
Andreas Hess et al.
GASTROENTEROLOGY (2015)
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Walter Reinisch et al.
GUT (2015)
Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
Jacob S. Lee et al.
IMMUNITY (2015)
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Joseph R. Maxwell et al.
IMMUNITY (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
Silvio Danese et al.
GUT (2015)
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Effect of IL-17A blockade with secukinumab in autoimmune diseases
Dhavalkumar D. Patel et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
Mark C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interleukin-17 Sensitizes Joint Nociceptors to Mechanical Stimuli and Contributes to Arthritic Pain Through Neuronal Interleukin-17 Receptors in Rodents
Frank Richter et al.
ARTHRITIS AND RHEUMATISM (2012)
Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
R. Kiesslich et al.
GUT (2012)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber et al.
GUT (2012)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Jonathan P. Sherlock et al.
NATURE MEDICINE (2012)
Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Nicolino Ruperto et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya et al.
GASTROENTEROLOGY (2011)
MEDICAL PROGRESS Ulcerative Colitis
Silvio Danese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
MECHANISMS OF DISEASE The Pathogenesis of Rheumatoid Arthritis
Iain B. McInnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells
Philip P. Ahern et al.
IMMUNITY (2010)
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Helen J. Lachmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion
Carlo Chizzolini et al.
BLOOD (2008)
Dickkopf-1 is a master regulator of joint remodeling
Danielle Diarra et al.
NATURE MEDICINE (2007)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
Richard H. Duerr et al.
SCIENCE (2006)
Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis
RJU Lories et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Mechanisms of disease: The effect of infections on susceptibility to autoimmune and allergic diseases
JF Bach
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial
S Cohen et al.
ARTHRITIS AND RHEUMATISM (2002)
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
WJ Sandborn et al.
GASTROENTEROLOGY (2001)
Claudins regulate the intestinal barrier in response to immune mediators
T Kinugasa et al.
GASTROENTEROLOGY (2000)
Share Paper
